JP6997178B2 - ベータラクタマーゼ阻害剤化合物 - Google Patents
ベータラクタマーゼ阻害剤化合物 Download PDFInfo
- Publication number
- JP6997178B2 JP6997178B2 JP2019515241A JP2019515241A JP6997178B2 JP 6997178 B2 JP6997178 B2 JP 6997178B2 JP 2019515241 A JP2019515241 A JP 2019515241A JP 2019515241 A JP2019515241 A JP 2019515241A JP 6997178 B2 JP6997178 B2 JP 6997178B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- alkoxy
- methyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCCCC=C(*)[C@@](*#C)NC(NO[C@@](C)(*)C(O)=O)=O Chemical compound CCCCCC=C(*)[C@@](*#C)NC(NO[C@@](C)(*)C(O)=O)=O 0.000 description 71
- GIKOYNVHNRQOEB-ROLXFIACSA-N BC(C(O[C@@H](C)CC)=O)F Chemical compound BC(C(O[C@@H](C)CC)=O)F GIKOYNVHNRQOEB-ROLXFIACSA-N 0.000 description 1
- JWMRGQFZTPOLCW-ZBHICJROSA-N B[C@H](C(O)OCCCC)F Chemical compound B[C@H](C(O)OCCCC)F JWMRGQFZTPOLCW-ZBHICJROSA-N 0.000 description 1
- XWARCKJYBAUGMZ-QMMMGPOBSA-N C=C[C@@H](CO)N(C(c1ccccc11)=O)C1=O Chemical compound C=C[C@@H](CO)N(C(c1ccccc11)=O)C1=O XWARCKJYBAUGMZ-QMMMGPOBSA-N 0.000 description 1
- WOPWYILHUMTINY-UHFFFAOYSA-O CC(C(C1)N2N=O)=CC(C([NH3+])=O)N1C2=O Chemical compound CC(C(C1)N2N=O)=CC(C([NH3+])=O)N1C2=O WOPWYILHUMTINY-UHFFFAOYSA-O 0.000 description 1
- YGHPHHFGJZGKPP-CFCGPWAMSA-N CC(C(O)=O)ON([C@@H]1C=C(C)[C@@H](CN)N2C1)C2=O Chemical compound CC(C(O)=O)ON([C@@H]1C=C(C)[C@@H](CN)N2C1)C2=O YGHPHHFGJZGKPP-CFCGPWAMSA-N 0.000 description 1
- UHHFKTYSCXIPPD-ZNMIVQPWSA-N CC(C)(C)OC(N1[C@H](CONC([C@H](C(C)=C[C@H](C2)N3OC)N2C3=O)=O)CCC1)=O Chemical compound CC(C)(C)OC(N1[C@H](CONC([C@H](C(C)=C[C@H](C2)N3OC)N2C3=O)=O)CCC1)=O UHHFKTYSCXIPPD-ZNMIVQPWSA-N 0.000 description 1
- SVQWFWGZIZAEBG-UXBLZVDNSA-N CC(C)/C=N/C(O)OC(C)(C)C Chemical compound CC(C)/C=N/C(O)OC(C)(C)C SVQWFWGZIZAEBG-UXBLZVDNSA-N 0.000 description 1
- SIBAGCZANHDBGR-SPOOISQMSA-N CC(C)OC(OC(C)OC([C@H](ONC(N1[C@H](C(N)=O)C(C)=CCCC1)=O)F)=O)=O Chemical compound CC(C)OC(OC(C)OC([C@H](ONC(N1[C@H](C(N)=O)C(C)=CCCC1)=O)F)=O)=O SIBAGCZANHDBGR-SPOOISQMSA-N 0.000 description 1
- IYTLVZUHBDOIQM-FZMZJTMJSA-N CC(C)OC([C@H](C)ONC(N1[C@H](C(N)=O)C(C2CC2)=CCCC1)=O)=O Chemical compound CC(C)OC([C@H](C)ONC(N1[C@H](C(N)=O)C(C2CC2)=CCCC1)=O)=O IYTLVZUHBDOIQM-FZMZJTMJSA-N 0.000 description 1
- ZLHNYIHIHQEHJQ-UHFFFAOYSA-N CC(NNC(C)=O)=O Chemical compound CC(NNC(C)=O)=O ZLHNYIHIHQEHJQ-UHFFFAOYSA-N 0.000 description 1
- WMUDMTKPJJWQSL-UHFFFAOYSA-N CC(NNC(SC)=N)=N Chemical compound CC(NNC(SC)=N)=N WMUDMTKPJJWQSL-UHFFFAOYSA-N 0.000 description 1
- XSJFKEVFSPGNJZ-JULQROHOSA-N CC([C@@H](C(NCC[C@H](CC1)NC1=O)=O)N(C1)C2=O)=C[C@H]1N2O[C@H](C(O)=O)F Chemical compound CC([C@@H](C(NCC[C@H](CC1)NC1=O)=O)N(C1)C2=O)=C[C@H]1N2O[C@H](C(O)=O)F XSJFKEVFSPGNJZ-JULQROHOSA-N 0.000 description 1
- PXTDOAOSSUTFGE-MNOVXSKESA-N CC([C@@H](C(NCc1nccnc1)=O)N(C1)C2=O)=C[C@H]1N2O Chemical compound CC([C@@H](C(NCc1nccnc1)=O)N(C1)C2=O)=C[C@H]1N2O PXTDOAOSSUTFGE-MNOVXSKESA-N 0.000 description 1
- JPCBOFGDAWACIJ-KOLCDFICSA-N CC([C@@H](C(NOCC(CC1)=NC1=O)=O)N(C1)C2=O)=C[C@H]1N2O Chemical compound CC([C@@H](C(NOCC(CC1)=NC1=O)=O)N(C1)C2=O)=C[C@H]1N2O JPCBOFGDAWACIJ-KOLCDFICSA-N 0.000 description 1
- QEEMJZXDEIFDDR-ZRUFSTJUSA-N CC([C@@H](C(NOC[C@H](C1)NCC1(F)F)=O)N(C1)C2=O)=C[C@H]1N2O[C@H](C(O)=O)F Chemical compound CC([C@@H](C(NOC[C@H](C1)NCC1(F)F)=O)N(C1)C2=O)=C[C@H]1N2O[C@H](C(O)=O)F QEEMJZXDEIFDDR-ZRUFSTJUSA-N 0.000 description 1
- AIONLMIVTTWRAC-PIJUOVFKSA-N CC([C@@H](C)N(C1)C(OC(C)(C)C)=O)C=C1O[Si+](C)(C)C Chemical compound CC([C@@H](C)N(C1)C(OC(C)(C)C)=O)C=C1O[Si+](C)(C)C AIONLMIVTTWRAC-PIJUOVFKSA-N 0.000 description 1
- IEJQSDMOTPNYII-YUMQZZPRSA-N CC([C@H](C1)N2OCCC(O)=O)=C[C@@H](C(N)=O)N1C2=O Chemical compound CC([C@H](C1)N2OCCC(O)=O)=C[C@@H](C(N)=O)N1C2=O IEJQSDMOTPNYII-YUMQZZPRSA-N 0.000 description 1
- KOZFVNZYDCDOCU-VIFPVBQESA-N CC([C@H]1C(NOCCS(N)(=O)=O)=O)=CCCCN1C(NO)=O Chemical compound CC([C@H]1C(NOCCS(N)(=O)=O)=O)=CCCCN1C(NO)=O KOZFVNZYDCDOCU-VIFPVBQESA-N 0.000 description 1
- IAPGTRMKHVDDKF-XVNBXDOJSA-N CC1OC1NOC/C=N/C Chemical compound CC1OC1NOC/C=N/C IAPGTRMKHVDDKF-XVNBXDOJSA-N 0.000 description 1
- RJBIOACDMBAJMM-UHFFFAOYSA-N CCC(CC)OC(C(C(F)(F)F)N)=O Chemical compound CCC(CC)OC(C(C(F)(F)F)N)=O RJBIOACDMBAJMM-UHFFFAOYSA-N 0.000 description 1
- BSSSVGWPHAMMOD-LURJTMIESA-N CCCCCOC([C@H](F)Br)=O Chemical compound CCCCCOC([C@H](F)Br)=O BSSSVGWPHAMMOD-LURJTMIESA-N 0.000 description 1
- KSYPSHHEORGLNR-WDEREUQCSA-N CCN([C@H](C(NCc1ncc[o]1)=O)C(C)=CN1O[C@H](C(O)=O)F)C1=O Chemical compound CCN([C@H](C(NCc1ncc[o]1)=O)C(C)=CN1O[C@H](C(O)=O)F)C1=O KSYPSHHEORGLNR-WDEREUQCSA-N 0.000 description 1
- IPAHUORDANLFLJ-HIFPTAJRSA-N CCOC(CON(C)C(N1C(CN)C=C(C)[C@@H](C)C1)=O)O Chemical compound CCOC(CON(C)C(N1C(CN)C=C(C)[C@@H](C)C1)=O)O IPAHUORDANLFLJ-HIFPTAJRSA-N 0.000 description 1
- GVUZRHFLKRNQDX-KCYTVLDUSA-N CCOC(CON([C@@H]1C(C)C(C)C(C(N)=O)N2C1)C2=O)=O Chemical compound CCOC(CON([C@@H]1C(C)C(C)C(C(N)=O)N2C1)C2=O)=O GVUZRHFLKRNQDX-KCYTVLDUSA-N 0.000 description 1
- OWSZGMJYDAKFRV-JQXSQYPDSA-N CCOC([C@@H](ONC(N1[C@H](C(CNCCC(N)=O)O)C(C)=CCCC1)=O)F)=O Chemical compound CCOC([C@@H](ONC(N1[C@H](C(CNCCC(N)=O)O)C(C)=CCCC1)=O)F)=O OWSZGMJYDAKFRV-JQXSQYPDSA-N 0.000 description 1
- UWHWQYAAFVGBER-MIMYLULJSA-N CCOC([C@H](ON([C@@H]1C=C(C2CC2)[C@@H](C(N)=O)N2C1)C2=O)F)=O Chemical compound CCOC([C@H](ON([C@@H]1C=C(C2CC2)[C@@H](C(N)=O)N2C1)C2=O)F)=O UWHWQYAAFVGBER-MIMYLULJSA-N 0.000 description 1
- VWBQHMCQXBRHJU-CIUDSAMLSA-N CC[C@@H](C(C)=C[C@@H](C#N)NC1=O)N1O[C@@H](C(O)=O)F Chemical compound CC[C@@H](C(C)=C[C@@H](C#N)NC1=O)N1O[C@@H](C(O)=O)F VWBQHMCQXBRHJU-CIUDSAMLSA-N 0.000 description 1
- USEGWGFGZVWYOI-CNZKWPKMSA-N CC[C@@H](C)OC(C(F)Br)=O Chemical compound CC[C@@H](C)OC(C(F)Br)=O USEGWGFGZVWYOI-CNZKWPKMSA-N 0.000 description 1
- GLJFOEDFKIATKY-UHFFFAOYSA-N N#CC(C1)C1(CC1)NC1=O Chemical compound N#CC(C1)C1(CC1)NC1=O GLJFOEDFKIATKY-UHFFFAOYSA-N 0.000 description 1
- UJOOMSDQMTXWAE-BYPYZUCNSA-N NOC[C@H](CC1)NC1=O Chemical compound NOC[C@H](CC1)NC1=O UJOOMSDQMTXWAE-BYPYZUCNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0892—Compounds with a Si-O-N linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021203942A JP7281527B2 (ja) | 2016-09-16 | 2021-12-16 | ベータラクタマーゼ阻害剤化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395464P | 2016-09-16 | 2016-09-16 | |
| US62/395,464 | 2016-09-16 | ||
| US201762456423P | 2017-02-08 | 2017-02-08 | |
| US62/456,423 | 2017-02-08 | ||
| PCT/US2017/051692 WO2018053215A1 (en) | 2016-09-16 | 2017-09-15 | Beta-lactamase inhibitor compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021203942A Division JP7281527B2 (ja) | 2016-09-16 | 2021-12-16 | ベータラクタマーゼ阻害剤化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532928A JP2019532928A (ja) | 2019-11-14 |
| JP2019532928A5 JP2019532928A5 (OSRAM) | 2020-10-01 |
| JP6997178B2 true JP6997178B2 (ja) | 2022-02-03 |
Family
ID=60083416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515241A Active JP6997178B2 (ja) | 2016-09-16 | 2017-09-15 | ベータラクタマーゼ阻害剤化合物 |
| JP2021203942A Active JP7281527B2 (ja) | 2016-09-16 | 2021-12-16 | ベータラクタマーゼ阻害剤化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021203942A Active JP7281527B2 (ja) | 2016-09-16 | 2021-12-16 | ベータラクタマーゼ阻害剤化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10800778B2 (OSRAM) |
| EP (1) | EP3512851B1 (OSRAM) |
| JP (2) | JP6997178B2 (OSRAM) |
| KR (2) | KR102537340B1 (OSRAM) |
| CN (2) | CN109715630B (OSRAM) |
| AU (1) | AU2017325863B2 (OSRAM) |
| CA (1) | CA3036557A1 (OSRAM) |
| DK (1) | DK3512851T3 (OSRAM) |
| ES (1) | ES2927986T3 (OSRAM) |
| HR (1) | HRP20221217T1 (OSRAM) |
| HU (1) | HUE060282T2 (OSRAM) |
| IL (2) | IL289686B2 (OSRAM) |
| LT (1) | LT3512851T (OSRAM) |
| MA (1) | MA46242A (OSRAM) |
| MX (2) | MX385507B (OSRAM) |
| PH (1) | PH12019500558B1 (OSRAM) |
| PL (1) | PL3512851T3 (OSRAM) |
| PT (1) | PT3512851T (OSRAM) |
| SG (1) | SG11201901658PA (OSRAM) |
| SI (1) | SI3512851T1 (OSRAM) |
| SM (1) | SMT202200397T1 (OSRAM) |
| TW (1) | TWI773687B (OSRAM) |
| WO (1) | WO2018053215A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| WO2018053215A1 (en) * | 2016-09-16 | 2018-03-22 | Entasis Therapeutics Limited | Beta-lactamase inhibitor compounds |
| US11046694B2 (en) | 2017-05-08 | 2021-06-29 | Entasis Therapeutics, Inc. | Compounds and methods for treating bacterial infections |
| EP3781576B1 (en) | 2018-04-20 | 2024-06-12 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| ES2960952T3 (es) | 2018-08-09 | 2024-03-07 | Antabio Sas | Diazabiciclooctanonas como inhibidores de serina beta-lactamasas |
| CN112209928B (zh) * | 2019-07-10 | 2023-02-17 | 华东理工大学 | 共价键标记丝氨酸类beta-内酰胺酶的试剂及制备和应用 |
| CN110898999A (zh) * | 2019-11-26 | 2020-03-24 | 中国矿业大学 | 一种煤焦油基煤泥浮选药剂及其制备方法 |
| CN111790439B (zh) * | 2020-07-29 | 2022-12-27 | 成都能特科技发展有限公司 | 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用 |
| EP4146650A4 (en) | 2020-09-01 | 2024-01-17 | Ningxia Academy of Agriculture and Forestry Sciences | BETA-LACTAMASE INHIBITORS AND THEIR PRODUCTION |
| KR20230167077A (ko) * | 2021-04-05 | 2023-12-07 | 큐펙스 바이오파마 인코포레이티드 | 세프티부텐 투여 요법 |
| EP4146651A4 (en) | 2021-05-07 | 2024-06-05 | Ningxia Academy of Agriculture and Forestry Sciences | SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS |
| US11814385B2 (en) * | 2021-06-25 | 2023-11-14 | University Of South Florida | Small molecule inhibitors targeting Clostridioides difficile sporulation |
| WO2023206580A1 (en) | 2022-04-29 | 2023-11-02 | Entasis Therapeutics Limited | Durlobactam crystalline forms |
| US20230398101A1 (en) * | 2022-06-09 | 2023-12-14 | Fleurir Abx Llc | Co-agents as Therapy Against Anaerobic Pathogens |
| CN118271319B (zh) * | 2022-12-30 | 2025-02-28 | 成都四面体药物研究有限公司 | 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途 |
| CN118772145B (zh) * | 2023-04-04 | 2025-10-10 | 上海医药工业研究院有限公司 | 一种二氮杂双环辛烯化合物的制备方法 |
| CN116693531A (zh) * | 2023-06-09 | 2023-09-05 | 河南师范大学 | 一种桥联多环内酰胺类化合物的合成方法 |
| WO2025106662A1 (en) * | 2023-11-15 | 2025-05-22 | Entasis Therapeutics, Inc. | Preparation of boronic acid intermediates useful for the preparation of compounds for treating bacterial infections |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011518871A (ja) | 2008-04-29 | 2011-06-30 | ノヴェクセル | アザビシクロ化合物、その調製及び医薬品、特にβ−ラクタマーゼ阻害剤としての使用 |
| JP2014515041A (ja) | 2011-08-27 | 2014-06-26 | ウォックハート リミテッド | １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用 |
| JP2015512440A (ja) | 2012-04-02 | 2015-04-27 | アストラゼネカ アクチボラグ | β−ラクタマーゼ阻害剤としてのヘテロ二環式化合物 |
| WO2016081452A1 (en) | 2014-11-17 | 2016-05-26 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
| JP2018510202A (ja) | 2015-03-31 | 2018-04-12 | ミュタビリスＭｕｔａｂｉｌｉｓ | 新規の複素環化合物及び細菌感染を予防又は治療する際のそれらの使用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607041A (en) * | 1983-04-27 | 1986-08-19 | Fisons Plc | Antihypertensive 2-phenyl Hantzsch dihydropyridines |
| ES2127946T3 (es) | 1993-12-29 | 1999-05-01 | Pfizer | Antagonistas de neurocinina diazabiciclica. |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2848210B1 (fr) | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| EP2231667B1 (en) | 2008-01-18 | 2013-09-04 | Merck Sharp & Dohme Corp. | Beta-lactamase inhibitors |
| EP2135959A1 (en) | 2008-06-19 | 2009-12-23 | Novexel | Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2937034B1 (fr) | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| BR112012026926B1 (pt) * | 2010-04-20 | 2021-01-19 | Taisho Pharmaceutical Co Ltd | composto derivado de ácido hidroxâmico, e composição farmacêutica, inibidor de lpxc e agente antimicrobiano compreendendo o referido composto |
| WO2013014496A1 (en) | 2011-07-26 | 2013-01-31 | Wockhardt Limited | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
| RU2569059C2 (ru) | 2011-07-26 | 2015-11-20 | Вокхардт Лимитед | Фармацевтические композиции, содержащие бета-лактамный антибиотик, сульбактам и ингибитор бета-лактамаз |
| BR112013032974A2 (pt) | 2011-08-30 | 2016-09-06 | Wockhardt Ltd | "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas". |
| MX349827B (es) | 2011-09-13 | 2017-08-14 | Wockhardt Ltd | Compuestos que contienen nitrogeno y su uso. |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| US20150119363A1 (en) | 2012-02-15 | 2015-04-30 | Rempex Pharmaceuticals, Inc.. | Methods of treating bacterial infections |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| US8927724B2 (en) | 2012-03-30 | 2015-01-06 | Cubist Pharmaceuticals, Inc. | Isoxazole beta-lactamase inhibitors |
| SG11201406123TA (en) | 2012-03-30 | 2014-10-30 | Cubist Pharm Inc | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS |
| SG10201605368UA (en) | 2012-05-30 | 2016-08-30 | Meiji Seika Pharma Co Ltd | NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME |
| EP2961751B1 (en) | 2012-08-25 | 2018-03-21 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections |
| CA2889793C (en) | 2012-09-03 | 2017-09-26 | Wockhardt Limited | Antibacterial compositions |
| BR112015018360B1 (pt) | 2013-02-06 | 2022-03-22 | Pfizer Anti-Infectives Ab | Combinação de ceftazidima, ou um sal farmaceuticamente aceitável da mesma, e avibactam, ou um sal farmaceuticamente aceitável do mesmo para o tratamento de pneumonia nosocomial |
| WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| WO2018053215A1 (en) * | 2016-09-16 | 2018-03-22 | Entasis Therapeutics Limited | Beta-lactamase inhibitor compounds |
| KR20230007830A (ko) * | 2021-07-06 | 2023-01-13 | 현대자동차주식회사 | 고강성 저선팽창 열가소성 수지 조성물 및 이를 포함하는 성형체 |
-
2017
- 2017-09-15 WO PCT/US2017/051692 patent/WO2018053215A1/en not_active Ceased
- 2017-09-15 PH PH1/2019/500558A patent/PH12019500558B1/en unknown
- 2017-09-15 PT PT177840634T patent/PT3512851T/pt unknown
- 2017-09-15 IL IL289686A patent/IL289686B2/en unknown
- 2017-09-15 SI SI201731232T patent/SI3512851T1/sl unknown
- 2017-09-15 US US16/333,900 patent/US10800778B2/en active Active
- 2017-09-15 SG SG11201901658PA patent/SG11201901658PA/en unknown
- 2017-09-15 JP JP2019515241A patent/JP6997178B2/ja active Active
- 2017-09-15 SM SM20220397T patent/SMT202200397T1/it unknown
- 2017-09-15 KR KR1020197010376A patent/KR102537340B1/ko active Active
- 2017-09-15 PL PL17784063.4T patent/PL3512851T3/pl unknown
- 2017-09-15 LT LTEPPCT/US2017/051692T patent/LT3512851T/lt unknown
- 2017-09-15 EP EP17784063.4A patent/EP3512851B1/en active Active
- 2017-09-15 MX MX2019003060A patent/MX385507B/es unknown
- 2017-09-15 HU HUE17784063A patent/HUE060282T2/hu unknown
- 2017-09-15 HR HRP20221217TT patent/HRP20221217T1/hr unknown
- 2017-09-15 KR KR1020237017457A patent/KR102667828B1/ko active Active
- 2017-09-15 CN CN201780057302.4A patent/CN109715630B/zh active Active
- 2017-09-15 MA MA046242A patent/MA46242A/fr unknown
- 2017-09-15 DK DK17784063.4T patent/DK3512851T3/da active
- 2017-09-15 ES ES17784063T patent/ES2927986T3/es active Active
- 2017-09-15 CA CA3036557A patent/CA3036557A1/en active Pending
- 2017-09-15 TW TW106131860A patent/TWI773687B/zh active
- 2017-09-15 AU AU2017325863A patent/AU2017325863B2/en active Active
- 2017-09-15 MX MX2021010077A patent/MX392515B/es unknown
- 2017-09-15 CN CN202210161577.5A patent/CN114591223B/zh active Active
-
2019
- 2019-03-11 IL IL265276A patent/IL265276B/en unknown
-
2021
- 2021-12-16 JP JP2021203942A patent/JP7281527B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011518871A (ja) | 2008-04-29 | 2011-06-30 | ノヴェクセル | アザビシクロ化合物、その調製及び医薬品、特にβ−ラクタマーゼ阻害剤としての使用 |
| JP2014515041A (ja) | 2011-08-27 | 2014-06-26 | ウォックハート リミテッド | １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用 |
| JP2015512440A (ja) | 2012-04-02 | 2015-04-27 | アストラゼネカ アクチボラグ | β−ラクタマーゼ阻害剤としてのヘテロ二環式化合物 |
| WO2016081452A1 (en) | 2014-11-17 | 2016-05-26 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
| JP2018510202A (ja) | 2015-03-31 | 2018-04-12 | ミュタビリスＭｕｔａｂｉｌｉｓ | 新規の複素環化合物及び細菌感染を予防又は治療する際のそれらの使用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6997178B2 (ja) | ベータラクタマーゼ阻害剤化合物 | |
| TWI597281B (zh) | β－內醯胺酶抑制劑化合物 | |
| JP7598594B2 (ja) | オキソ置換化合物 | |
| RU2741496C2 (ru) | Гетероциклические соединения и их применение в лечении или предотвращении бактериальных инфекций | |
| KR102671585B1 (ko) | 거대환형 광범위 항생제 | |
| TW201722967A (zh) | 雜環化合物及其用於預防或治療細菌感染之用途 | |
| JP7589139B2 (ja) | 複素環式化合物及び細菌感染の予防又は治療へのそれらの使用 | |
| JP7550421B2 (ja) | オキソ置換化合物からなる医薬 | |
| HK40011101B (en) | Beta-lactamase inhibitor compounds | |
| HK40011101A (en) | Beta-lactamase inhibitor compounds | |
| EA037916B1 (ru) | Соединения-ингибиторы бета-лактамаз | |
| BR112019005053B1 (pt) | Compostos inibidores de beta-lactamase, usos dos mesmos, composição farmacêutica, e processo para formação de um composto | |
| EA044428B1 (ru) | Соединения-ингибиторы бета-лактамаз | |
| NZ791470A (en) | Beta-lactamase inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200820 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210607 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210823 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211125 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211216 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6997178 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |